Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, AbbVie Inc. and Blueprint Medicines Corporation have taken different paths in optimizing these costs.

AbbVie, a giant in the industry, has seen its SG&A expenses grow by approximately 66% from 2014 to 2023. Despite this increase, the company has maintained a steady growth trajectory, reflecting its robust market position and strategic investments. In contrast, Blueprint Medicines, a smaller player, has experienced a staggering 3,640% rise in SG&A costs over the same period. This sharp increase highlights the company's aggressive expansion strategy and its commitment to innovation.

While AbbVie's expenses are significantly higher in absolute terms, Blueprint's rapid growth in SG&A costs underscores its ambitious drive to capture market share and enhance its competitive edge.